PERI-EDU University Education
Diabetes is not an automatic contraindication to implant therapy. Risk is better understood through current glycaemic control, diabetes-related complications, local inflammatory burden, procedural demands and the patient’s capacity for long-term maintenance. HbA1c contributes important context, but it cannot independently predict osseointegration or peri-implant disease.
Diabetes is a heterogeneous clinical context
Type 1 diabetes is primarily caused by autoimmune destruction of pancreatic beta cells and requires insulin replacement. Type 2 diabetes is dominated by insulin resistance with progressive beta-cell dysfunction. Glycaemic control can be stable or unstable in either type, and two people with the same diagnosis may have very different vascular health, complication burden, glucose variability and treatment needs.
| Clinical dimension | Type 1 diabetes | Type 2 diabetes | Implant-care relevance |
|---|---|---|---|
| Dominant mechanism | Autoimmune beta-cell destruction and absolute insulin deficiency. | Insulin resistance with progressive beta-cell dysfunction. | The diagnosis alone does not describe current stability. |
| Treatment | Insulin is essential. | Lifestyle measures and one or more medicines; insulin may be required. | The dental team records treatment but does not alter it. |
| Complications | Microvascular, neural, renal, cardiovascular and immune effects may occur. | Complication burden may matter more than diabetes type alone. | |
How hyperglycaemia may influence peri-implant tissues
Persistent hyperglycaemia can affect vascular, immune and skeletal pathways involved in wound healing and host defence. Advanced glycation, endothelial dysfunction, oxidative stress and altered immune-cell behaviour may impair tissue repair or prolong inflammation. Osteoblast differentiation and coupled bone remodelling may also be affected.
These mechanisms do not allow one-to-one prediction of an individual outcome. Hyperglycaemia may modify the host response to a biofilm or surgical wound, but it does not replace local explanations such as plaque retention, periodontitis, implant malposition, prosthetic inaccessibility, residual cement or excess load.
What the clinical evidence supports
Earlier reviews were inconclusive because studies used small samples, different definitions of peri-implant disease and poorly standardized categories of glycaemic control. More recent systematic reviews and dose-response analyses generally indicate that peri-implant bleeding, probing depth, marginal bone change and healing indicators become less favourable as glycaemic exposure increases. Study heterogeneity and confounding still limit precise risk estimates.
| Question | Evidence-informed answer | Important boundary |
|---|---|---|
| Is diabetes an absolute contraindication? | No. Implant therapy can be successful when systemic and local conditions are stable. | Published success rates do not guarantee safety for every patient. |
| Does poorer control matter? | Higher HbA1c and poorly controlled diabetes are associated in several reviews with worse peri-implant parameters and more complications. | Study categories vary and do not establish a universal cutoff. |
| Does good control remove risk? | Outcomes may be closer to those observed without diabetes. | Local, vascular, behavioural and mechanical risks still apply. |
| Can HbA1c predict one implant? | No. It adds useful information but cannot independently predict healing or disease. | A single value omits variability, complications and local conditions. |
The 2023 EFP guideline recommends promotion of glycaemic control for peri-implant health. This is clinically coherent and consistent with general diabetes care, but it does not validate one HbA1c threshold for every implant procedure.
Interpreting HbA1c responsibly
HbA1c approximates average glycaemic exposure over the preceding two to three months, with greater influence from recent weeks. Record the exact value, date and source rather than using only labels such as “good” or “poor” control. A trend may be more informative than one result.
HbA1c can be distorted by anaemia, altered red-cell turnover, haemoglobin variants, recent transfusion, pregnancy and advanced kidney disease. Individual medical targets also differ with age, comorbidity, hypoglycaemia risk and treatment goals.
Although some studies report poorer outcomes in categories above approximately 8%, this does not establish 8% as a universal cancellation threshold. Procedure extent, infection, urgency, vascular health, previous healing and current medical stability must also be considered.
Pre-operative assessment
- Clarify current metabolic stability: review recent HbA1c when relevant, major treatment changes, severe hypoglycaemia, hyperglycaemic crisis and acute illness.
- Identify diabetes-related complications: cardiovascular, renal, neurological, visual, vascular and previous healing problems may influence care.
- Review medicines and meal timing: avoid unplanned fasting and follow the patient-specific medical plan.
- Control local inflammation: assess periodontitis, plaque, mucosal health, active infection and prosthetic cleansability.
- Match the plan to combined risk: consider surgical extent, grafting, primary stability, loading and capacity for maintenance.
Medical coordination should answer a focused question: Is the condition stable? Is the available HbA1c current and interpretable? Are complications or medication considerations relevant to the planned procedure? Dental clinicians should not independently change insulin, glucose-lowering medicines or individualized glycaemic targets.
Local disease control remains the foundation
Periodontal and peri-implant diseases are biofilm-associated inflammatory conditions. Metabolic dysregulation may increase susceptibility or impair inflammatory resolution, but it does not diminish the importance of plaque control, correct implant position and an accessible prosthetic design.
- Treat active periodontitis and infection before elective implant surgery.
- Confirm that the planned restoration can be cleaned and professionally monitored.
- Record baseline peri-implant findings for longitudinal comparison.
- Do not use antibiotics as a substitute for metabolic or local disease control.
- Do not defer urgent care or basic infection control solely because glycaemic optimization is incomplete.
Surgery and early healing
Appointment planning should respect the patient’s meal and medicine schedule and anticipate hypoglycaemia. Extensive grafting or complex therapy may be staged when combined risk warrants it. Atraumatic technique, stable fixation, tissue preservation and early review remain central.
Worsening pain, spreading swelling, purulence, fever or systemic deterioration require prompt evaluation. Post-operative hyperglycaemia is nonspecific and may reflect pain, infection, physiological stress or disrupted meals; it should not be used to diagnose a surgical complication without clinical examination.
Supportive care over time
Recall intervals should be based on combined risk rather than diabetes diagnosis alone. Current metabolic stability, history of periodontitis, plaque levels, smoking, prosthetic access, bleeding or suppuration, previous peri-implant disease and attendance all contribute.
| At supportive visits | Document | Respond |
|---|---|---|
| Update health status | Medication changes, HbA1c when clinically relevant, complications and acute events. | Coordinate if instability could affect care or healing. |
| Assess tissues | Plaque, bleeding, suppuration, probing depth, recession and tenderness. | Investigate repeated or progressive findings. |
| Compare with baseline | Site-specific probing and radiographic changes when indicated. | Diagnose from longitudinal clinical and radiographic evidence. |
| Review access and function | Occlusion, prosthesis integrity and ability to clean. | Modify the hygiene strategy or prosthesis when needed. |
Clinical synthesis
- Diabetes is not an automatic contraindication to implant treatment.
- Record exact HbA1c values and dates when they are relevant; do not use a universal eligibility threshold.
- Control active local disease while systemic health is optimized in parallel.
- Sequence elective invasive therapy according to systemic stability and procedure complexity.
- Use focused medical coordination and do not independently change diabetes medication.
- Base long-term maintenance on combined metabolic, periodontal, behavioural and prosthetic risk.
Download the full educational material
The extended PDF provides the full biological framework, evidence interpretation, HbA1c limitations, pre-operative pathway, surgical considerations and supportive-care strategy.
Download the full educational material (PDF)
Selected references
- Herrera D, Berglundh T, Schwarz F, et al. Prevention and treatment of peri-implant diseases: the EFP S3 level clinical practice guideline. Journal of Clinical Periodontology. 2023;50(Suppl 26):4-76. doi:10.1111/jcpe.13823.
- Tan SJ, Baharin B, Nabil S, et al. The influence of glycemic control on implant survival and peri-implant parameters: a systematic review and meta-analysis. 2021.
- Systematic review on diabetes mellitus and dental implants: an update. 2022. PMID: 34978649.
- Impact of hyperglycemia on dental implant failure and peri-implant parameters: a systematic review and meta-analysis. 2021.
- Bencze M, et al. Association between glycaemic status and peri-implant conditions in type 2 diabetes and prediabetes. 2024.
- Dental implant outcomes in patients with diabetes mellitus: a systematic review. 2026.
Explore related PERI-EDU resources
#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #Diabetes #GlycaemicControl #HbA1c #ImplantCare
This educational material does not replace individual clinical assessment, diabetes care, emergency protocols, laboratory interpretation or procedure-specific guidance.
This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.